Kim Yoonjung, Kim Seong Eun, Kim Tark, Yun Ki Wook, Lee So Hee, Lee Eunjung, Seo Jun-Won, Jung Young Hee, Chong Yong Pil
Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Korea.
Division of Infectious Diseases, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Infect Chemother. 2022 Sep;54(3):566-597. doi: 10.3947/ic.2022.0141.
Long-lasting coronavirus disease 2019 (COVID-19) symptoms beyond 12 weeks, the so-called 'long COVID' have been increasingly reported worldwide. Long COVID can be manifested in various forms, and there is an increasing demand for proper assessment and management. However, it is challenging when trying to determine the best-practice standards of care based on the current evidence because there is no internationally agreed clinical definition or clear treatment pathway. Therefore, the present guidelines have been drafted to provide advice on diagnosis and management based on the latest updated available evidence and the consensus of expert opinion. So far, no standard test and drug treatment can be strongly recommended for patients with long COVID because of a lack of evidence. The present guidelines provide advice based on 12 key questions, including appropriate interventions for long COVID that can be used in clinical practice. Continuous careful observation and studies related to long COVID are needed for the long-term impact of COVID-19 and proper management for long COVID to be determined.
全球范围内越来越多地报告了持续超过12周的2019冠状病毒病(COVID-19)症状,即所谓的“长新冠”。长新冠可表现为多种形式,对其进行恰当评估和管理的需求也日益增加。然而,基于目前的证据来确定最佳治疗标准具有挑战性,因为尚无国际公认的临床定义或明确的治疗途径。因此,本指南旨在根据最新可得证据和专家意见共识,就诊断和管理提供建议。到目前为止,由于缺乏证据,无法强烈推荐针对长新冠患者的标准检测和药物治疗。本指南基于12个关键问题提供建议,包括可用于临床实践的长新冠适当干预措施。为了确定COVID-19的长期影响以及对长新冠进行恰当管理,需要对长新冠进行持续的仔细观察和相关研究。